Total Payments
$2.2M
2024 Payments
$226,785
Companies
46
Transactions
3,373
Medicare Patients
1,875
Medicare Billing
$9.6M
Payment Breakdown by Category
Other$1.5M (68.4%)
Consulting$393,097 (17.8%)
Travel$211,898 (9.6%)
Food & Beverage$67,747 (3.1%)
Research$22,587 (1.0%)
Education$1,249 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 519 | 67.7% |
| Consulting Fee | $393,097 | 94 | 17.8% |
| Travel and Lodging | $211,898 | 900 | 9.6% |
| Food and Beverage | $67,747 | 1,803 | 3.1% |
| Unspecified | $22,587 | 17 | 1.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $8,118 | 2 | 0.4% |
| Grant | $4,000 | 2 | 0.2% |
| Charitable Contribution | $2,000 | 1 | 0.1% |
| Education | $1,249 | 35 | 0.1% |
Payments by Type
General
$2.2M
3,356 transactions
Research
$22,587
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $672,001 | 784 | $0 (2024) |
| Biogen, Inc. | $564,046 | 941 | $0 (2024) |
| EMD Serono, Inc. | $349,422 | 496 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $166,401 | 312 | $0 (2024) |
| Genentech USA, Inc. | $152,190 | 186 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $103,963 | 107 | $0 (2024) |
| Celgene Corporation | $69,015 | 191 | $0 (2024) |
| TG Therapeutics, Inc. | $31,398 | 71 | $0 (2024) |
| Acorda Therapeutics, Inc | $26,281 | 39 | $0 (2021) |
| Novartis Pharma AG | $15,371 | 6 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $226,785 | 382 | EMD Serono, Inc. ($140,411) |
| 2023 | $190,261 | 353 | EMD Serono, Inc. ($103,110) |
| 2022 | $188,539 | 374 | Biogen, Inc. ($71,242) |
| 2021 | $126,253 | 235 | Biogen, Inc. ($49,257) |
| 2020 | $117,248 | 185 | Biogen, Inc. ($49,188) |
| 2019 | $411,838 | 607 | GENZYME CORPORATION ($172,353) |
| 2018 | $439,254 | 563 | GENZYME CORPORATION ($197,762) |
| 2017 | $503,162 | 674 | GENZYME CORPORATION ($217,693) |
All Payment Transactions
3,373 individual payment records from CMS Open Payments — Page 1 of 135
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $99.46 | General |
| Category: Neuroscience | ||||||
| 12/23/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $28.70 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/20/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $19.61 | General |
| 12/20/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $4.04 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 12/18/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: Neurology | ||||||
| 12/16/2024 | GENZYME CORPORATION | LEMTRADA (Biological) | — | Cash or cash equivalent | $8,625.00 | Research |
| Study: A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) • Category: Neurology | ||||||
| 12/16/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $31.74 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $9.86 | General |
| Category: Neuroscience | ||||||
| 12/16/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $2.36 | General |
| Category: Neuroscience | ||||||
| 12/13/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $23.95 | General |
| Category: Neurology | ||||||
| 12/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $145.28 | General |
| Category: Immunology | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $27.87 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/09/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,287.20 | General |
| 12/07/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $25.45 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $514.57 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $212.19 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,450.00 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/04/2024 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,228.00 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $90.70 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | Cash or cash equivalent | $39.51 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/04/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $23.39 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) | GENZYME CORPORATION | $14,250 | 5 |
| OFA-MS -111171 Dispelling the Myths: Practical Considerations for Managing Pregnancy in Patients With MS | Novartis Pharmaceuticals Corporation | $2,763 | 1 |
| HEOR | Novartis Pharmaceuticals Corporation | $2,711 | 1 |
| MS700568-0079 | EMD Serono, Inc. | $1,339 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $957.57 | 1 |
| MS700568-0078 | EMD Serono, Inc. | $566.61 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 456 | 83,584 | $4.6M | $2.4M |
| 2022 | 12 | 499 | 85,761 | $4.9M | $2.4M |
| 2021 | 11 | 463 | 87,047 | $5.5M | $2.4M |
| 2020 | 12 | 457 | 91,575 | $6.1M | $2.4M |
Total Patients
1,875
Total Services
347,967
Medicare Billing
$9.6M
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2323 | Injection, natalizumab, 1 mg | Office | 2023 | 19 | 53,700 | $2.0M | $1.0M | 51.3% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2023 | 20 | 18,000 | $1.5M | $768,638 | 51.5% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2023 | 12 | 1,890 | $457,380 | $250,036 | 54.7% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 19 | 7,995 | $348,662 | $241,606 | 69.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 86 | 575 | $201,250 | $70,066 | 34.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 140 | 203 | $45,675 | $30,346 | 66.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 46 | 319 | $38,280 | $21,721 | 56.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 34 | 257 | $38,550 | $6,443 | 16.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 26 | 83 | $12,450 | $4,696 | 37.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $4,900 | $2,386 | 48.7% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 40 | 548 | $8,110 | $2,167 | 26.7% |
| J2323 | Injection, natalizumab, 1 mg | Office | 2022 | 20 | 53,100 | $2.0M | $976,749 | 50.0% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2022 | 21 | 18,600 | $1.7M | $767,485 | 45.2% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 18 | 9,435 | $411,460 | $281,026 | 68.3% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2022 | 12 | 2,100 | $508,200 | $277,628 | 54.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 83 | 492 | $172,200 | $64,781 | 37.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 143 | 229 | $51,525 | $35,427 | 68.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 40 | 121 | $14,240 | $8,715 | 61.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 24 | 131 | $19,650 | $8,328 | 42.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 35 | 230 | $34,500 | $6,164 | 17.9% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2022 | 46 | 1,074 | $15,895 | $4,617 | 29.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 44 | 236 | $11,800 | $3,133 | 26.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $4,550 | $2,441 | 53.6% |
| J2323 | Injection, natalizumab, 1 mg | Office | 2021 | 26 | 57,000 | $2.1M | $1.0M | 49.3% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2021 | 17 | 15,600 | $2.1M | $645,710 | 30.6% |
About Dr. Heidi Crayton, MD
Dr. Heidi Crayton, MD is a Neurology healthcare provider based in Vienna, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1669470720.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Heidi Crayton, MD has received a total of $2.2M in payments from pharmaceutical and medical device companies, with $226,785 received in 2024. These payments were reported across 3,373 transactions from 46 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Crayton has provided services to 1,875 Medicare beneficiaries, totaling 347,967 services with total Medicare billing of $9.6M. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Vienna, VA
- Active Since 07/13/2005
- Last Updated 03/05/2008
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1669470720
Products in Payments
- TYSABRI (Biological) $426,938
- LEMTRADA (Drug) $338,669
- AUBAGIO (Drug) $289,931
- Mavenclad (Drug) $200,580
- ZEPOSIA (Drug) $117,854
- OCREVUS (Biological) $99,267
- GILENYA (Drug) $97,011
- MAVENCLAD (Drug) $79,568
- Non-Covered Product (Drug) $45,759
- Ozanimod (Drug) $35,127
- BRIUMVI (Drug) $29,215
- AMPYRA (Drug) $26,265
- Mavenclad (Biological) $23,439
- MAYZENT (Drug) $22,979
- Gilenya (Drug) $15,371
- LEMTRADA (Biological) $14,331
- KESIMPTA (Drug) $12,348
- Tysabri (Biological) $8,733
- Rebif (Biological) $7,525
- PONVORY (Drug) $3,674
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Vienna
Dr. Nancy Hu, M.d, M.D
Neurology — Payments: $48,445
Neurology $48,445
Dr. Navid Mostofi, Md, MD
Neurology — Payments: $4,176
Neurology $4,176
Dr. Adam Lewis, M.d, M.D
Neurology — Payments: $932.94
Neurology $932.94
Dr. John Seok, M.d, M.D
Neurology — Payments: $713.78
Neurology $713.78
Dr. Gary Blabey, Dc, DC
Neurology — Payments: $324.04
Neurology $324.04
Leonard Dasilva, Md, MD
Neurology — Payments: $32.27
Neurology $32.27